β-Nicotinamide Mononucleotide
nmn
NMN is a direct NAD+ precursor; raising blood NAD+ at 250–1,000 mg/day is the most consistently reproduced human finding (2024 meta-analysis: 12 RCTs, n=513). Muscle insulin sensitivity improved in peri-menopausal women at 250 mg for 10 weeks (Yoshino 2021, Science), and no serious adverse events were reported up to 1,200 mg/day for 24 weeks. However, a 2025 meta-analysis in older adults found no significant gain in muscle mass or grip strength — NAD+ elevation is established, functional benefit is still under study. What matters when choosing: published β-purity ≥99%, an actual daily dose of ≥250 mg, and price per 100 mg.
See the standard















